Poolbeg Pharma PLC (POLB.L)

GBp 7.18

(-2.31%)

Market Cap (In GBp)

35.9 Million

Revenue (In GBp)

-

Net Income (In GBp)

-3.93 Million

Avg. Volume

1.29 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.96-15.767
PE
-
EPS
-
Beta Value
2.138
ISIN
GB00BKPG7Z60
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeremy Skillington Ph.D.
Employee Count
-
Website
https://www.poolbegpharma.com
Ipo Date
2021-07-19
Details
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.